# Kiniksa Pharmaceuticals International, plc (KNSA)

> Source: Nexqual · https://nexqual.com/KNSA · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Kiniksa Pharmaceuticals International, plc (KNSA), nexqual.com/KNSA" · informational, not investment advice.

**Price:** USD 80.79 (+1.37% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 79.7 · day 78.39–81.28 · 52w 35.2–84.06 · market cap $6.30B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $841M, net income $80.7M (9.6% margin), free cash flow $183M (SEC filings).
- Valuation: P/E 78.2x (avg 72.4x at the last 2 fiscal year-ends).
- Analysts: Buy (mean 1.88 on a 1–5 scale) (8 analysts), mean target USD 98 (range 87–108).
- Total return with dividends: 1Y +108.4% vs S&P 500 +14.9%; 5Y +653.6% vs S&P 500 +80.3%.
- Next earnings: 2026-10-27, EPS estimate USD 0.32, revenue estimate $260M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $38.5M | $220M | $270M | $423M | $678M | $841M |
| Gross profit | $29.4M | $197M | $237M | $362M | $600M | — |
| Operating income | -$157M | $9.8M | -$25.2M | -$45.6M | $77.2M | $100M |
| Net income | -$158M | $183M | $14.1M | -$43.2M | $59.0M | $80.7M |
| EPS (diluted) | -$2.30 | $2.60 | $0.20 | -$0.60 | $0.75 | — |
| Free cash flow | -$127M | $5.7M | $13.2M | $25.4M | $136M | $183M |
| Gross margin | 76.4% | 89.6% | 87.6% | 85.6% | 88.5% | — |
| Operating margin | -406.4% | 4.4% | -9.3% | -10.8% | 11.4% | 11.9% |
| Net margin | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% | 9.6% |
| Revenue growth | — | +471.2% | +22.7% | +56.6% | +60.1% | — |
| Cash + short-term investments | $182M | $191M | $206M | $244M | $414M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 78.2x · P/S 7.5x · P/FCF 34.5x · P/B 9.6x · FCF yield 2.90% · Earnings yield 1.28%
P/E at fiscal year-ends: Dec 2025 55.2x, Dec 2023 89.6x.

## Analysts
Consensus Buy (mean 1.88 on a 1–5 scale), 8 analysts; mean target USD 98 (low 87, high 108).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-30 | Goldman Sachs | Target raised | Buy | $75 → $90 |
| 2026-07-29 | JP Morgan | Target raised | Overweight | $72 → $107 |
| 2026-07-29 | Canaccord Genuity | Target raised | Buy | $64 → $98 |
| 2026-07-29 | Wedbush | Target raised | Outperform | $72 → $99 |
| 2026-07-29 | Citigroup | Target raised | Buy | $60 → $100 |
| 2026-07-23 | Goldman Sachs | Target raised | Buy | $60 → $75 |
| 2026-07-13 | Wells Fargo | Target raised | Overweight | $57 → $74 |
| 2026-06-29 | Wedbush | Target raised | Outperform | $59 → $72 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +108.4% | +653.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +108.9% | +49.6% |
| Volatility (annualized) | 47.5% | 50.6% |
| Max drawdown | -21.1% (May 2026→Jun 2026) | -45.7% (Nov 2021→May 2022) |

## Peers (Drug Manufacturers - Specialty & Generic)
LNTH (Lantheus Holdings, Inc.) USD 100.1 -0.14% · HIMS (Hims & Hers Health, Inc.) USD 29.13 -0.27% · AMRX (Amneal Pharmaceuticals, Inc.) USD 20.48 +1.39% · ALKS (Alkermes plc) USD 44.18 +1.61% · RGC (Regencell Bioscience Holdings L) USD 9.81 -9.17% · INDV (Indivior Pharmaceuticals, Inc.) USD 35.33 +1.55%

## More
Full page: https://nexqual.com/KNSA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-07-28)

- "Financial Guidance ● Kiniksa expects 2026 ARCALYST net product revenue of between $980 million and $995 million, compared to prior guidance of between $930 million and $945 million. ● Kiniksa expects its current operating plan to remain cash flow positive on an annual basis. ​ Conference Call Information ● Kiniksa will host a conference call and webcast at 8:30 a.m."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.32 | $0.31 | +2.4% | $260.2M | 4 |
| Next quarter (ends 2026-12-31) | $0.29 | $0.29 | -2.5% | $276.2M | 4 |
| Current fiscal year (ends 2026-12-31) | $1.16 | $1.16 | -0.2% | $994.4M | 4 |
| Next fiscal year (ends 2027-12-31) | $1.62 | $1.70 | -5.0% | $1.22B | 4 |